Neoleukin Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Neurogene

14/11/2022 22:28

* Neoleukin Therapeutics Inc  NLTX.OQ  reported a quarterly
adjusted loss of 24 cents​​ per share for the quarter ended in
September. The mean expectation of seven analysts for the
quarter was for a loss of 30 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Neoleukin Therapeutics Inc's reported EPS for the quarter
was a
loss of 24 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Neoleukin Therapeutics Inc shares had fallen by 15.6% this
quarter and lost 88.8% so far this year.
    * The company reported a quarterly loss of $13.09 million.
    * Wall Street's median 12-month price target for Neoleukin
Therapeutics Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
14 at 10:28 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.30          -0.24          Beat
 Jun. 30 2022      -0.30          -0.28          Beat
 Mar. 31 2022      -0.30          -0.28          Beat
 Dec. 31 2021      -0.30          -0.28          Beat